en
Scientific article
English

Optimizing seroprotection against pneumococcus in children with nephrotic syndrome using the 13-valent pneumococcal conjugate vaccine

Published inVaccine, vol. 34, no. 41, p. 4948-4954
Publication date2016
Abstract

Infections are among the main life-threatening complications in patients with nephrotic syndrome (NS), in particular with Streptococcus pneumoniae, the first cause of bacterial peritonitis and sepsis in these patients. This study aims to evaluate the baseline seroprotection of NS patients against S. pneumoniae, and immunize them with the 13-valent pneumococcal conjugate vaccine (PCV13) regardless of disease activity and previous immunization history, in order to evaluate the immunogenicity, safety profile, and effect of NS treatment on vaccine responses.

Citation (ISO format)
PITTET, Laure et al. Optimizing seroprotection against pneumococcus in children with nephrotic syndrome using the 13-valent pneumococcal conjugate vaccine. In: Vaccine, 2016, vol. 34, n° 41, p. 4948–4954. doi: 10.1016/j.vaccine.2016.08.049
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0264-410X
487views
3downloads

Technical informations

Creation11/29/2016 12:13:00 PM
First validation11/29/2016 12:13:00 PM
Update time03/15/2023 1:04:35 AM
Status update03/15/2023 1:04:35 AM
Last indexation05/02/2024 5:59:53 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack